Aotai Bio's net profit in 2021 is 761 million yuan, an increase of 12.11% over the same period
On February 25, Aotai Biotech released a performance report, achieving an operating income of 1.888 billion yuan in 2021, an increase of 66.27% over the same period last year; the net profit attributable to shareholders of the parent company was 761 million yuan, an increase of 12.11% over the same period of the previous year; The net profit attributable to owners of the parent company after deducting non-recurring gains and losses was 726 million yuan, an increase of 7.83% over the same period of the previous year.
In 2021, the global COVID-19 situation is still severe. The company fully responds to the market demand for COVID-19 products, and continues to develop and improve a series of COVID-19 detection products such as COVID-19 antigen (nasal swab) rapid detection and COVID-19 antigen (saliva) rapid detection. The company has obtained the European CE self-test, Australian TGA, Malaysia, Singapore and other multi-country new crown product registration certificates, which will promote the company's overall business performance in 2021 to achieve steady growth.In 2021, the company's operating income increased by 66.27% over the previous year, mainly due to the continuous growth in sales of new crown detection reagents during the reporting period, which led to the continued growth of operating income.
In 2021, the company's weighted average return on net assets decreased by 77.28 percentage points compared with the previous year, mainly because: due to the availability of raised funds during the reporting period, the growth rate of net assets was much higher than that of net profit.
At the end of 2021, the company's total assets increased by 247.31% compared with the beginning of the year, the owner's equity attributable to the parent company increased by 236.24% compared with the beginning of the year, and the net assets per share attributable to owners of the parent company increased by 152.06% compared with the beginning of the year. The increase in operating income and undistributed profit during the reporting period also led to a substantial increase in the size of the company's assets.
*Disclaimer: This article is written by the author who is stationed in Sina Pharmaceutical News. The views only represent the author and do not represent the position of Sina Pharmaceutical News.